Still expensive, but a solution is within reach
08/10/19 -"According the press, an out of court settlement for all Glyphosat-based cases seems now to be on Mr Baumann's agenda. Having lost the three original cases in the US, the idea of settling all of them ..."
Pages
74
Language
English
Published on
08/10/19
You may also be interested by these reports :
30/09/26
Lundbeck, as per Bloomberg, is pursuing endocrine- and neurology-focused Xeris Biopharma, whose market cap is c.28% of that of Lundbeck. Considering ...
24/09/26
A years/decades long search for revolutionary multi-blockbuster drug(s), a phenomenal run for some years and then concerns sprout around ...
21/09/26
Novo’s CMD announcements, including the diversification plan and a vague mid-term sales target, disappointed investors. Against the backdrop of ...
21/09/26
Siegfried’s (Buy, Switzerland) post-Covid success story has been nipped in the bud by three years of low-single-digit (LSD) growth (in CHF). ...